Hemab Secures $157m in Funding for Bleeding Disorder Treatments
Hemab Therapeutics has successfully completed an oversubscribed Series C funding round, raising $157m to further develop therapies for bleeding disorders.
Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.
- The investment round was led by Sofinnova Partners.
- A global asset management company also contributed to the round.
- New investors, including a sovereign wealth fund and Avoro Capital Advisors, joined the round.
- Existing stakeholders, such as Access Biotechnology, Avoro Ventures, and Novo Holdings, continued their support.
No direct quote available in the text.
As a result of this financial milestone, Sofinnova partner Joe Anderson will join the Hemab board.
Author's summary: Hemab raises $157m for bleeding disorder treatments.
More News
- New HUNT Proven Trail Carbon Wheels On Test
- MLB: The Last 10 World Series MVPs
- Elon Musk's xAI Launches Grok-powered 'Grokipedia' Encyclopedia
- Cloud's new performance leader: Arm beats x86
- Solving Jacksonville Jaguars' pass rush issues starts with Josh Hines-Allen
- Would you board an AI-piloted airliner?
- BIMZELX® (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spon
- The United States Is Broke. Americans May Not Care - But the World Does - The Heartland Institute
- Exploring the Flawlessness of Nature - Blood: River of Red Gold
- How to Download and Play Battlefield 6 Battle Royale (RedSec)